A treatment for the polyneuropathy of hATTR amyloidosis in adultsA treatment for the polyneuropathy of hATTR amyloidosis in adultsA treatment for the polyneuropathy of hATTR amyloidosis in adults
A treatment for the polyneuropathy of hATTR amyloidosis in adultsA treatment for the polyneuropathy of hATTR amyloidosis in adultsA treatment for the polyneuropathy of hATTR amyloidosis in adults

ONPATTRO® (patisiran) can reverse polyneuropathy manifestations of the disease4

ONPATTRO is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

At 18 months in a placebo-controlled study, ONPATTRO demonstrated:

  • Reversal in neuropathy impairment from baseline as measured by modified Neuropathy Impairment Score + 7 (mNIS+7)4
  • Improvement in quality of life from baseline as measured by Norfolk Quality of Life-Diabetic Neuropathy (QoL-DN) score4

 

green leaf

Get started
with ONPATTRO®

 
green leaf

Sign up to
stay informed